英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：


请选择你想看的字典辞典：
单词字典翻译
994264查看　994264　在百度字典中的解释百度英翻中〔查看〕
994264查看　994264　在Google字典中的解释Google英翻中〔查看〕
994264查看　994264　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • Eye Injections for Retinal Diseases | EYLEA® (aflibercept) Injection
    EYLEA® (aflibercept) Injection 2 mg is a prescription medicine approved for the treatment of patients with Wet Age-Related Macular Degeneration (AMD), Macular Edema following Retinal Vein Occlusion (RVO), Diabetic Macular Edema (DME), and Diabetic Retinopathy (DR)
  • EYLEA HD (aflibercept) Injection 8 mg Approved by FDA for Treatment of . . .
    EYLEA HD (aflibercept) Injection 8 mg Approved by FDA for Treatment of
  • Eylea Injection Treatment for Wet Macular Degeneration
    Regeneron Pharmaceuticals announced that the FDA has approved its Eylea injection treatment for wet age-related macular degeneration (AMD) The treatment, known in the scientific literature as VEGF Trap-Eye, was approved at a recommended dose of 2 mg every four weeks for the first twelve weeks, followed by 2 mg dose every two months (1 2)
  • FACT SHEET ABOUT EYLEA (aflibercept) INJECTION
    IMPORTANT PRESCRIBING INFORMATION FOR EYLEA® (aflibercept) INJECTION EYLEA® (aflibercept) Injection is a prescription medicine approved for the treatment of patients with: Wet age-related macular degeneration (AMD): The recommended dose for EYLEA is 2 mg administered by injection in the eye every 2 months (8 weeks) following 3 initial
  • Eylea Patient Tips: 7 things you should know - Drugs. com
    Eylea or Eyela HD treatment for Wet AMD may involve fewer eye injections per year compared to other Wet AMD treatments Eylea is usually injected every 4 or 8 weeks depending upon your condition, but some patients may be able to have injections every 12 weeks after 1 year of treatment
  • New Product Applications: Lengthening the Time Between Treatments
    Regeneron’s Eylea HD (aflibercept) injection 8 mg allows patients with wet age-related macular degeneration (wAMD), diabetic macular edema (DME), and diabetic retinopathy (DR) to receive less frequent treatment injections after their initial monthly doses than its predecessor, Eylea (aflibercept) injection 2 mg, while still experiencing similar visual gains and anatomic improvements with the
  • Regeneron Pharmaceuticals receive FDA approval for Eylea HD
    TARRYTOWN, N Y , Aug 18, 2023 (GLOBE NEWSWIRE) — Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) today announced that the U S Food and Drug Administration (FDA) has approved EYLEA HD (aflibercept) Injection 8 mg for the treatment of patients with wet age-related macular degeneration (wAMD), diabetic macular edema (DME) and diabetic
  • FDA Rejects Regeneron’s sBLA to Extend EYLEA HD Dosing Interval
    Regeneron’s proposal to lengthen EYLEA HD dosing intervals to 24 weeks hits a CRL roadblock The wait for extended treatment intervals with anti-VEGF agents in exudative retinal diseases continues Regeneron (New Jersey, United States) announced Friday that the U S Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL
  • Regeneron reveals positive results from multiple trials evaluating . . .
    EYLEA HD (known as Eylea 8 mg in the European Union and Japan) is being jointly developed by Regeneron and Bayer AG References: EYLEA HD® (aflibercept) Injection 8 mg Positive Phase 3 Results in Patients with Macular Edema following Retinal Vein Occlusion Presented at Angiogenesis Meeting Published February 8, 2025
  • Regeneron Reports Positive Three-Year Results for EYLEA HD Treatment in . . .
    Regeneron Pharmaceuticals announced positive three-year results from an extension study of EYLEA HD (aflibercept) Injection 8 mg for treating wet age-related macular degeneration (wAMD) The





中文字典-英文字典  2005-2009